|
PureTech Health PLC - clinical-stage biotherapeutics company - Says it will advance LYT-300 for the potential treatment of anxiety disorders and post-partum depression. A placebo-controlled, phase 2a, proof-of-concept, social anxiety clinical trial is expected to begin in the first half of 2023. Results are expected by the end of the year. An open-label, phase 2a, proof-of-concept clinical trial in women with post-partum depression is expected to begin in the second half of 2023. Current stock price: 233.50 pence, down 1.7% in London on Tuesday afternoon 12-month change: down 15% Copyright 2023 Alliance News Ltd. All Rights Reserved.
|
